Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | $0.00 | $26.0M | $64.0K |
| Revenue growth | — | — | -99.8% |
| Operating income | -$69.1M | -$22.5M | -$58.1M |
| Operating margin | — | -86.2% | -90740.6% |
| Net income | -$62.1M | -$15.6M | -$55.5M |
| Net margin | — | -60.0% | -86687.5% |
| EPS (diluted) | -$1.13 | -$0.28 | -$1.00 |
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Operating cash flow | -$47.7M | -$23.6M | -$51.2M |
| Capital expenditures | $81.0K | $750K | $434K |
| Free cash flow | -$47.8M | -$24.4M | -$51.6M |
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Cash & equivalents | $106M | $78.2M | $38.3M |
| Total assets | $127M | $101M | $56.1M |
| Total liabilities | $25.9M | $9.12M | $14.1M |
| Shareholders' equity | $101M | $92.2M | $42.0M |
| Retained earnings | -$330M | -$345M | -$401M |
| Shares (wtd avg diluted) | 55.1M | 55.2M | 55.7M |
Every figure is extracted from Connect Biopharma Holdings Ltd’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.